Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP47 | Q96K76 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | LIG1 | P18858 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7060968 | 0.85 | PKM (0.58) | USP47ALDH1A1HPGDHSD17B2HSD17B1 | |
| SCHEMBL11400595 | 0.84 | PKM (0.56) | USP47ALDH1A1HPGDHSD17B2HSD17B1 | |
| SCHEMBL11392259 | 0.84 | PKM (0.56) | USP47ALDH1A1HPGDHSD17B2HSD17B1 | |
| SCHEMBL13056224 | 0.83 | LMNA (0.40) | USP47ALDH1A1HPGDHSD17B2HSD17B1 | |
| SCHEMBL9724133 | 0.81 | USP7 (0.60) | USP47HSD17B2HSD17B1PKMNPC1 | |
| SCHEMBL11392258 | 0.81 | HSD17B2 (0.47) | USP47ALDH1A1HPGDHSD17B2HSD17B1 | |
| SCHEMBL11400592 | 0.81 | HSD17B2 (0.47) | USP47ALDH1A1HPGDHSD17B2HSD17B1 | |
| SCHEMBL9724101 | 0.78 | HSD17B1 (0.48) | ALDH1A1HPGDHSD17B2HSD17B1MAPT | |
| SCHEMBL2786198 | 0.76 | LMNA (0.54) | USP47ALDH1A1HPGDHSD17B2HSD17B1 | |
| SCHEMBL6940078 | 0.76 | HPGD (0.43) | ALDH1A1HPGDHSD17B2HSD17B1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8652752-B2 | Sulphonium salt initiators | BASF SE (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8652752-B2 | Sulphonium salt initiators | BASF SE (DE) | 2014-02-18 | — | — | US | disclosed |
| EP-2197869-B1 | SULPHONIUM SALT INITIATORS | BASF SE (DE) | 2013-04-24 | — | — | EP | disclosed |
| US-20100297540-A1 | SULPHONIUM SALT INITIATORS | BASF SE (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100297540-A1 | SULPHONIUM SALT INITIATORS | BASF SE (DE) | 2010-11-25 | — | — | US | disclosed |
| WO-2009047105-A1 | SULPHONIUM SALT INITIATORS | BASF SE (CH) | 2009-04-16 | — | — | WO | disclosed |
| EP-1086091-A4 | HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6262055-B1 | SULFUR-CONTAINING HETEROARYL DIOXO-BUTYRIC ACID DERIVATIVES | MERCK & CO., INC. | 2001-07-17 | — | — | US | disclosed |
| EP-1086091-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999062897-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0588785-A1 | UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-03-30 | — | — | EP | disclosed |
| US-5185363-A | Administering for treatment of inflammatory diseases | ABBOTT LABORATORIES (US) | 1993-02-09 | — | — | US | disclosed |
| EP-0588785-A4 | UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS. | ABBOTT LAB (US) | 1991-12-30 | — | — | EP | disclosed |
| WO-1990012008-A1 | UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1990-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297540-A1 | SULPHONIUM SALT INITIATORS | SULT1A1, SULT2A1, NCOA1 | USP47 4349/4885ALDH1A1 1081/4885HPGD 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.